Paper Details

  1. Home
  2. Paper Details

Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections.

Author: ChenXuefu, GanWeiqiang, GaoZhiliang, LiJianguo, LinChaoshuang, ZhangChunlan

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

A 104-week regimen of telbivudine (LdT) was found to be safe and effective in treating chronic hepatitis B (CHB) in Chinese patients with HBeAg-negative. Of the 108 patients enrolled in the study, 94% achieved virological suppression after 104 weeks. The majority of patients (81%) were able to maintain LdT monotherapy for the entire duration of the study, while the remaining 20% required the addition of adefovir (ADV). The HBsAg titre declined steadily throughout the study, and the eGFR increased steadily.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Evaluate the safety and efficacy of 104-week regimen of Telbivudine(LdT)-based optimization strategy for Chinese patients who have chronic hepatits B(CHB) with HBeAg-negative. METHODS: This multi-center, open-label, prospective study enrolled 108 HBeAg-negative CHB patients who received...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720458/

データ提供：米国国立医学図書館（NLM）

Telbivudine-Based Optimization Strategy for Chronic Hepatitis B

This study examines the safety and efficacy of a 104-week telbivudine (LdT)-based optimization strategy for treating chronic hepatitis B (CHB) in patients with HBeAg-negative infection. The researchers conducted a prospective, open-label study involving patients who received LdT monotherapy for 24 weeks, followed by the addition of adefovir (ADV) if HBV DNA remained detectable. They assessed the virological, biochemical, and safety outcomes of this treatment strategy. Their findings demonstrate the long-term effectiveness and safety of this optimization strategy in achieving durable virological suppression and improving liver function in patients with HBeAg-negative CHB.

Optimizing Treatment Outcomes

The study demonstrates the effectiveness of the LdT-based optimization strategy in achieving long-term virological suppression and improving liver function in patients with HBeAg-negative CHB. The researchers observed high rates of HBV DNA suppression and ALT normalization at 24 weeks, which were sustained throughout the 104-week study period. This optimization strategy offers a promising approach for managing HBeAg-negative CHB and improving long-term outcomes for patients.

Managing Chronic Hepatitis B

If you’re living with chronic hepatitis B, it’s crucial to work closely with your doctor to develop a personalized treatment plan. The study highlights the potential of the LdT-based optimization strategy for achieving long-term virological suppression and improving liver function. However, individual responses to medications can vary, and it’s essential to be vigilant about potential side effects and to communicate any concerns with your doctor.

Dr.Camel's Conclusion

This study offers valuable insights into the long-term effectiveness and safety of a telbivudine-based optimization strategy for treating chronic hepatitis B in patients with HBeAg-negative infection. The researchers demonstrate the strategy’s ability to achieve durable virological suppression and improve liver function. This research contributes to the ongoing efforts to optimize treatment outcomes for patients with chronic hepatitis B and improve their long-term health and well-being.

Date :
  1. Date Completed 2020-12-21
  2. Date Revised 2020-12-21
Further Info :

Pubmed ID

33287722

DOI: Digital Object Identifier

PMC7720458

Related Literature

Article Analysis
・Effects of telbivudine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.